Publication:
Drug assessment by a Pharmacy and Therapeutics committee: from drug selection criteria to use in clinical practice.

Loading...
Thumbnail Image

Date

2014-07-09

Authors

Lozano-Blázquez, Ana
Calvo-Pita, Cecilia
Carbajales-Álvarez, Mónica
Suárez-Gil, Patricio
Martínez-Martínez, Fernando
Calleja-Hernández, Miguel Ángel

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Dove Medical Press
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

BACKGROUND In Spain, hospital medicines are assessed and selected by local Pharmacy and Therapeutics committees (PTCs). Of all the drugs assessed, cancer drugs are particularly important because of their budgetary impact and the sometimes arguable added value with respect to existing alternatives. This study analyzed the PTC drug selection process and the main objective was to evaluate the degree of compliance of prescriptions for oncology drugs with their criteria for use. METHODS This was a retrospective observational study (May 2007 to April 2010) of PTC-assessed drugs. The variables measured to describe the committee's activity were number of drugs assessed per year and number of drugs included in any of these settings: without restrictions, with criteria for use, and not included in formulary. These drugs were also analyzed by therapeutic group. To assess the degree of compliance of prescriptions, a score was calculated to determine whether prescriptions for bevacizumab, cetuximab, trastuzumab, and bortezomib were issued in accordance with PTC drug use criteria. RESULTS The PTC received requests for inclusion of 40 drugs, of which 32 were included in the hospital formulary (80.0%). Criteria for use were established for 28 (87.5%) of the drugs included. In total, 293 patients were treated with the four cancer drugs in eight different therapeutic indications. The average prescription compliance scores were as follows: bevacizumab, 83% for metastatic colorectal cancer, 100% for metastatic breast cancer, and 82.3% for non-small-cell lung cancer; cetuximab, 62.0% for colorectal cancer and 50% for head and neck cancer; trastuzumab, 95.1% for early breast cancer and 82.4% for metastatic breast cancer; and bortezomib, 63.7% for multiple myeloma. CONCLUSION The degree of compliance with criteria for use of cancer drugs was reasonably high. PTC functions need to be changed so that they can carry out more innovative tasks, such as monitoring conditions for drug use.

Description

Journal Article;

MeSH Terms

Medical Subject Headings::Health Care::Health Services Administration::Organization and Administration::Professional Practice::Professional Staff Committees::Pharmacy and Therapeutics Committee
Medical Subject Headings::Psychiatry and Psychology::Psychological Phenomena and Processes::Mental Processes::Thinking::Decision Making
Medical Subject Headings::Health Care::Health Services Administration::Organization and Administration::Pharmacy Administration::Drug Utilization
Medical Subject Headings::Information Science::Information Science::Communications Media::Publications::Books::Reference Books::Formularies as Topic
Medical Subject Headings::Diseases::Neoplasms
Medical Subject Headings::Information Science::Information Science::Communications Media::Publications::Books::Reference Books::Formularies as Topic::Formularies, Hospital

DeCS Terms

CIE Terms

Keywords

decision-making, drug selection, drug utilization, formulary, neoplasm, Pharmacy and Therapeutics committee, Comité Farmacéutico y Terapéutico, Toma de Decisiones, Utilización de Medicamentos, Formularios Farmacéuticos como Asunto, Formularios de Hospitales

Citation

Lozano-Blázquez A, Calvo-Pita C, Carbajales-Álvarez M, Suárez-Gil P, Martínez-Martínez F, Calleja-Hernández MÁ. Drug assessment by a Pharmacy and Therapeutics committee: from drug selection criteria to use in clinical practice. Ther Clin Risk Manag. 2014; 10:527-35